Objective: The purpose of this study was to compare intensive insulin therapy and conventional therapy in terms of ventilator days, neurosurgical intensive care unit (NSICU) stay, Glasgow Outcome Scale (GOS), and complications for patients with a severe traumatic brain injury (TBI) who underwent decompressive craniectomy. Methods: Patients who had a TBI and a Glasgow Coma Scale (GCS) score ≤8, and who had been treated with a unilateral or bilateral decompressive craniectomy were enrolled. Twenty-three patients were treated with intensive insulin therapy targeting 80-120 mg/dL of blood glucose level. For comparison, 17 patients with conventional insulin therapy (＜200 mg/dL) were extracted from the historical data. Results: There was no statistically significant difference in terms of sex, age, GCS at admission, diagnosis of TBI, and history of diabetes. There was no statistically significant difference between the conventional and intensive groups with respect to total days of mechanical ventilation, NSICU days, GOS, and pneumonia. Hypoglycemic episodes developed more frequently in the intensive insulin therapy group than in the conventional therapy group. Conclusion: Intensive insulin therapy with our protocol cannot be recommended over conventional therapy in patients with severe TBI. 
Introduction
Following acute traumatic brain injury, stress induced catecholamine release can result in elevated blood glucose levels. Hyperglycemia has been considered a stress response and a simple reflection of the injury severity. 10) In animal studies of ischemic and hemorrhagic stroke, hyperglycemia has been associated with increased ischemic brain damage, edema, and peri-lesional cell death. Early hyperglycemia in rats with traumatic brain injury (TBI) was associated with a larger contusion area and increased inflammation. 12, 13) Current guidelines for acute ischemic stroke suggest that interventions are indicated if a glucose level is greater than 180 mg/dL. 1) Since a landmark trial which demonstrated a significant decrease in mortality using intensive insulin protocol targeting blood glucose levels between 80 and 110 mg/dL in surgical intensive care patients, tight glucose control has been widely adopted in the critical setting.
14)
Traditionally, the authors have collaborated with endocrinologists for the control of hyperglycemia in neurosurgical intensive care unit (NSICU), especially in cases with more than 200 mg/dL of blood glucose level. The different treatments affect the clinical outcomes of patients with severe TBI. Therefore, we focus on the craniectomy, a uniform surgical intervention that is widely performed and useful for the treatment of TBI. Here, we have evaluated the feasibility of intensive insulin therapy for patients with severe TBI who underwent decompressive craniectomy.
Materials and Methods
Patients eligible for enrollment were patients who had a TBI and Glasgow Coma Scale (GCS) score ≤8, and who were treated with decompressive craniectomy unilaterally and/ or bilaterally. Between January 2007 and December 2008, 23 patients were enrolled for the study and treated with intensive insulin therapy. Blood glucose levels were obtained via fingerstick (capillary) testing every 1 hr initially and reduced to every 2 hr as levels stabilized. A continuous insulin infusion (250 units regular insulin in 500 milliliters of 0.9% sodium chloride solution) was delivered via a central or peripheral venous catheter and titrated for a goal blood sugar of 80 to 120 mg/dL (Table 1) . Patients deemed to be approaching death based on the following criteria were excluded: GCS of 3 without sedation; systolic blood pressure ＜50 mmHg or heart rate ＜40 despite vasoactive drugs; oxygen saturation of less than 90% despite FiO2 of 100% oxygenation. Blood glucose levels were measured at admission to NSICU and at least every 2 hr thereafter during intensive care unit (ICU) stay. Intensive insulin therapy continued throughout the study. Data on demographic and clinical characteristics were obtained at baseline.
Historic control (n=17) was extracted from medical records and radiological reviews of TBI patients (GCS ≤8) who had undergone decompressive craniectomy, between 2004 and 2006. The blood glucose was measured every 6 hr via fingerstick (capillary) testing. Treatment was initiated with a goal blood sugar of less than 200 mg/dL, whenever the blood sugar level was greater than 200 mg/dL. Regular insulin (RI) was administered subcutaneously with 4 units of RI for a blood sugar of 201 to 249 mg/dL and increased stepwise by 4 units for every 50 mg/dL higher range, thereafter.
All patients had been fed an enteral diet via a nasogastric tube, as soon as possible after NSICU admission. When patients were discharged from NSICU, conventional management of blood sugar was performed by blood sugar measurements every 8-hr via fingerstick to target a blood sugar for less than 200 mg/dL.
For the statistical comparison, we performed Student's ttest and chi-square test using the SPSS 12 software package for Windows (SPSS, Inc., Chicago, IL, USA). A p-value of less than 0.05 was considered statistically significant.
Results
Patients' characteristics are shown in Table 2 . Twentythree patients were treated with intensive insulin therapy following decompressive craniectomy for the treatment of severely traumatic brain injury. For the comparison between the intensive insulin therapy and conventional control (＜200 mg/dL of blood sugar), 17 patients with conventional insulin therapy were extracted from the historical data. There was no statistically significant difference in terms of sex, age, GCS at admission, diagnosis of TBI, and a history of diabetes.
Clinical outcomes are summarized in Table 3 . There was Intensive Insulin Therapy for Severe Traumatic Brain Injury no statistically significant difference between the conventional and intensive groups with respect to the total days of mechanical ventilation, ICU days, Glasgow Outcome Scale (GOS) and pneumonia. Hypoglycemic episodes developed more frequently in the intensive insulin therapy group rather than in the conventional therapy group. Hypoglycemic events were accompanied by diaphoresis, arrhythmia, or increased respiratory rate and heart rate. The intensive insulin therapy was finished in 2 patients within 5 days after ICU admission, because of repeated episodes of hypoglycemia. Fluid overloading developed in 2 patients during our protocol of intensive insulin therapy.
Discussion
In this study, we showed that in patients admitted to a N-SICU after decompressive craniectomy for the treatment of severe TBI, intensive insulin therapy titrated to maintain strict blood glucose control (blood glucose levels at 80-120 mg/dL) has no significant benefits on the clinical outcomes and increases the risk of hypoglycemia and fluid overloading.
Previous studies indicate that systemic hyperglycemia is harmful because it contributes to anaerobic metabolism in the brain following acute injury, resulting in brain tissue lactic acidosis and secondary neuronal injury. 16, 18) However, it is not determined to what degree glucose should be targeted in TBI patients to improve clinical outcomes. It is reported that the admission glucose ＞200 mg/dL was associated with poor outcomes. 17) A glucose value of 200 mg/dL was chosen as the cut-off because it was accepted as a treatable number in clinical practice. A different study demonstrated that patients with severe TBI had significantly higher glucose levels compared to those with mild TBI and found that blood glucose levels ＞150 mg/dL on admission were associated with poorer neurologic outcomes. 9) Additionally, it was observed that blood admission glucose levels ＞150 mg/dL at admission was associated with higher in-hospital mortality. 15) On the other hand, it was reported that blood glucose levels ＞170 mg/dL were associated with poor outcomes. 8) Hyperglycemia is transient following acute TBI, and is indicative of poor outcomes. It is suggested that therapeutic intervention for controlling hyperglycemia needs to be initiated within the first 24 h of admission. 3, 5) Total dosage of insulin administered for intensive insulin therapy during the early period should be calculated to convert to intermittent insulin administration. Hypoglycemic episodes were more frequent in the intensive insulin therapy group. A recent randomized trial that examined intensive insulin therapy in critically ill patients was halted early due to a lack of efficacy and increased incidence of hypoglycemia. 4) In neurological patients here may be more of a concern with having even low normal blood glucose levels and its impact on intracerebral glucose availability and metabolism and, ultimately, on neurologic recovery. 2, 11) In our series, the lack of benefit of intensive insulin therapy could be related with the higher risk of hypoglycemia. Additionally, our protocol (Table 1) has the risk of fluid overloading for patients with intractable hyperglycemia. Given these results, intensive insulin therapy with our protocol (targeting 80-120 mg/dL of blood glucose level) cannot be recommended over conventional therapy (targeting ＜200 mg/dL of blood glucose level). 6,7) Currently, intensive insulin therapy is performed in selected TBI patients whose hyperglycemia is not controlled with conventional therapy and have tolerable cardiopulmonary function.
Conclusion
There was no benefit to intensive insulin therapy for severe TBI patients in terms of ventilator days, ICU stay, GOS, and pneumonia according to the single institution's experience. Moreover, the risk of hypoglycemic episodes and fluid overloading was increased.
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